Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

A biosensor-based approach toward purification and crystallization of G protein-coupled receptors.

Navratilova I, Pancera M, Wyatt RT, Myszka DG.

Anal Biochem. 2006 Jun 15;353(2):278-83. Epub 2006 Apr 18.

PMID:
16647033
2.

Solubilization, stabilization, and purification of chemokine receptors using biosensor technology.

Navratilova I, Sodroski J, Myszka DG.

Anal Biochem. 2005 Apr 15;339(2):271-81.

PMID:
15797568
3.

Capture and reconstitution of G protein-coupled receptors on a biosensor surface.

Stenlund P, Babcock GJ, Sodroski J, Myszka DG.

Anal Biochem. 2003 May 15;316(2):243-50.

PMID:
12711346
4.

Analyzing ligand and small molecule binding activity of solubilized GPCRs using biosensor technology.

Navratilova I, Dioszegi M, Myszka DG.

Anal Biochem. 2006 Aug 1;355(1):132-9. Epub 2006 May 15.

PMID:
16762304
5.

Electrostatic modeling of peptides derived from the V3-loop of HIV-1 gp120: implications of the interaction with chemokine receptor CCR5.

Morikis D, Rizos AK, Spandidos DA, Krambovitis E.

Int J Mol Med. 2007 Mar;19(3):343-51.

PMID:
17273779
6.

Functional reconstitution of the HIV receptors CCR5 and CD4 in liposomes.

Devesa F, Chams V, Dinadayala P, Stella A, Ragas A, Auboiroux H, Stegmann T, Poquet Y.

Eur J Biochem. 2002 Nov;269(21):5163-74.

7.

Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.

Yoshimura K, Shibata J, Kimura T, Honda A, Maeda Y, Koito A, Murakami T, Mitsuya H, Matsushita S.

AIDS. 2006 Oct 24;20(16):2065-73.

PMID:
17053352
8.

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.

PLoS Pathog. 2007 Aug 24;3(8):e117.

9.

Large-scale expression and purification of the major HIV-1 coreceptor CCR5 and characterization of its interaction with RANTES.

Nisius L, Rogowski M, Vangelista L, Grzesiek S.

Protein Expr Purif. 2008 Oct;61(2):155-62. doi: 10.1016/j.pep.2008.06.001. Epub 2008 Jun 8.

PMID:
18588983
10.

Selection and characterization of an HIV-1 gp120-binding affibody ligand.

Wikman M, Rowcliffe E, Friedman M, Henning P, Lindholm L, Olofsson S, Ståhl S.

Biotechnol Appl Biochem. 2006 Sep;45(Pt 2):93-105.

PMID:
16712522
11.

Detergent screening of a G-protein-coupled receptor using serial and array biosensor technologies.

Rich RL, Miles AR, Gale BK, Myszka DG.

Anal Biochem. 2009 Mar 1;386(1):98-104. doi: 10.1016/j.ab.2008.12.011. Epub 2008 Dec 24.

14.

Structural basis for the interaction between focal adhesion kinase and CD4.

Garron ML, Arthos J, Guichou JF, McNally J, Cicala C, Arold ST.

J Mol Biol. 2008 Feb 1;375(5):1320-8. Epub 2007 Nov 22.

PMID:
18078954
15.

CD4 and CCR5 constitutively interact at the plasma membrane of living cells: a confocal fluorescence resonance energy transfer-based approach.

Gaibelet G, Planchenault T, Mazères S, Dumas F, Arenzana-Seisdedos F, Lopez A, Lagane B, Bachelerie F.

J Biol Chem. 2006 Dec 8;281(49):37921-9. Epub 2006 Oct 11.

16.

Phosphatidylcholine-specific phospholipase C activation is required for CCR5-dependent, NF-kB-driven CCL2 secretion elicited in response to HIV-1 gp120 in human primary macrophages.

Fantuzzi L, Spadaro F, Purificato C, Cecchetti S, Podo F, Belardelli F, Gessani S, Ramoni C.

Blood. 2008 Apr 1;111(7):3355-63. doi: 10.1182/blood-2007-08-104901. Epub 2008 Jan 18.

17.

Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120.

Binley JM, Ngo-Abdalla S, Moore P, Bobardt M, Chatterji U, Gallay P, Burton DR, Wilson IA, Elder JH, de Parseval A.

Retrovirology. 2006 Jul 3;3:39. Erratum in: Retrovirology. 2007;4:23.

18.

Gp120 V3-dependent impairment of R5 HIV-1 infectivity due to virion-incorporated CCR5.

Monde K, Maeda Y, Tanaka Y, Harada S, Yusa K.

J Biol Chem. 2007 Dec 21;282(51):36923-32. Epub 2007 Oct 30.

19.

Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.

Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP.

PLoS Pathog. 2009 Aug;5(8):e1000548. doi: 10.1371/journal.ppat.1000548. Epub 2009 Aug 14.

20.

In vitro reconstitution and preparative purification of complexes between the chemokine receptor CXCR4 and its ligands SDF-1alpha, gp120-CD4 and AMD3100.

Dukkipati A, Vaclavikova J, Waghray D, Garcia KC.

Protein Expr Purif. 2006 Dec;50(2):203-14. Epub 2006 Aug 1.

PMID:
16962791
Items per page

Supplemental Content

Write to the Help Desk